cardiovascular
ApoC3 targeted by Sirnaomics through its announced completion of IND-Enabling studies of safety and efficacy for STP125G with NHP Models
July 15, 2024Research and Development Cardiology, RNAi therapeutics, Sirnaomics, biopharmaceutical, cardiovascular, investigational new drug
Sirnaomics, a biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, has announced the completion of IND-enabling studies …
AstraZeneca’s Forxiga approved in China for chronic heart failure treatment
August 18, 2023Medical Communications AstraZeneca, Cardiology, China, cardiovascular, heart failure
AstraZeneca has announced that Forxiga (dapagliflozin) has been approved in China to reduce the risk of cardiovascular death, hospitalisation for …
Novo Nordisk’s Wegovy reduces risk of cardiovascular events
August 9, 2023Research and Development Cardiology, Novo Nordisk, Wegovy, cardiovascular, cvd, semaglutide
Novo Nordisk has shared results from the SELECT cardiovascular outcomes trial, which show that a once weekly subcutaneous dose of …
Amarin gains positive opinion from Spanish Drug Pricing Committee for national reimbursement of Vazkepa in Spain
July 26, 2023Sales and Marketing Amarin, Cardiology, Spanish Drug Pricing Committee, Vazkepa, cardiovascular
Amarin has announced that the Spanish Drug Pricing Committee has recommended the national reimbursement of Vazkepa (icosapent ethyl) in Spain …
First ever human implant of fully artificial heart announced
July 15, 2021cardiovascular
CARMAT has announced that the first ever human implantation of their fully artificial heart, which was designed as a therapeutic …
Phoenix Cardiac gains CE Mark for “game-changer” MR device
April 26, 2021Sales and Marketing CE Mark, EU, cardiovascular
Phoenix Cardiac Devices have received CE Mark certification for its BACE (basal annuloplasty of the cardia externally) device, a novel …
MHRA gives green light to new cardiovascular treatment
April 23, 2021Medical Communications MHRA, cardiovascular
The MHRA has granted a Great Britain Marketing Authorisation for Vazkepa (icosapent ethyl) as a treatment to reduce the risk …
Significant lack of women and minorities involved in clinical trials for cardiometabolic medication, research shows
June 1, 2020Sales and Marketing cardio, cardiovascular, cvd
Women and minorities, particularly African Americans, continue to be under represented in clinical trials for cardiometabolic medication, according to a …
ACC.20 cancelled due to coronavirus fears
March 9, 2020Manufacturing and Production, Medical Communications cardio, cardiology, cardiovascular
The American College of Cardiology has cancelled its upcoming ACC.20 event with the World Congress of Cardiology due to concerns …
Insider Interview: Reducing the risk of adverse cardiovascular events
February 3, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Insider Interview, cardiovascular, heart disease, pharma
Rodrigo Gribble, Vice President Cardiovascular at AstraZeneca, breaks down recently published data from the PEGASUS trial of ticagrelor, a potential …
Heart disease deaths increase for first time in 50 years
May 13, 2019Sales and Marketing BHF, UK, cardiovascular, health, heart disease, obesity
Deaths from heart disease among people under the age of 75 have increased for the first time in 50 years. …
Janssen’s Invokana combo smashes primary and secondary endpoints in chronic kidney disease
April 16, 2019Manufacturing and Production, Research and Development Janssen, cardiovascular, chronic kidney disease, diabetes, invokana, pharma
Janssen has unveiled promising new Phase 3 for its sodium-glucose transport (SGLT) protein-2 inhibitor Invokana (canagliflozin), showing that the therapy …
AZ’s Farxiga reduces major adverse cardiovascular event risk in type 2 diabetes, new data shows
March 19, 2019Manufacturing and Production, Research and Development AstraZeneca, cardiovascular, farxiga, pharma
AstraZeneca has lifted the curtain on new Phase 3 data for its sodium-glucose co-transporter 2 (SGLT2) inhibitor Farxiga (dapagliflozin), reinforcing …
Sanofi and Regeneron’s Praluent approved in Europe to reduce CV risk
March 18, 2019Research and Development, Sales and Marketing Regeneron, Sanofi, cardiovascular, heart, praluent
Sanofi and Regeneron’s Praluent (alirocumab) has been awarded approval by the European Commission, it has emerged, as a therapy to …
FDA approve valsartan generic after shortages of supply
March 13, 2019Manufacturing and Production, Research and Development FDA, blood pressure drugs, cardiovascular, generic, valsartan
The FDA has approved a new generic version of blood pressure drug valsartan. The approval comes amid shortages in supply …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
